BELLUS Health (OTCMKTS:BLUSF) announced its quarterly earnings results on Wednesday. The company reported ($0.02) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.01) by ($0.01), MarketWatch Earnings reports. The firm had revenue of $0.01 million for the quarter. BELLUS Health had a negative net margin of 26,317.24% and a negative return on equity of 33.10%.

OTCMKTS BLUSF traded up $0.07 during trading on Friday, hitting $1.07. The company had a trading volume of 14,903 shares, compared to its average volume of 26,707. BELLUS Health has a one year low of $0.37 and a one year high of $1.28.

TRADEMARK VIOLATION WARNING: This story was published by Watch List News and is owned by of Watch List News. If you are reading this story on another domain, it was illegally copied and republished in violation of United States & international trademark and copyright legislation. The correct version of this story can be accessed at

About BELLUS Health

BELLUS Health Inc, a clinical-stage biopharmaceutical company, develops novel therapeutics for conditions with high unmet medical need. Its lead drug candidate includes BLU-5937, a small molecule antagonist of the P2X3 receptor for chronic cough. The company also has economic interests in various partnered development stage programs, including KIACTA for the treatment of sarcoidosis; AMO-01 for treatment of Phelan McDermid syndrome; and ALZ-801 for APOE4 homozygous Alzheimer's disease.

See Also: What is required to own or exchange cryptocurrency?

Earnings History for BELLUS Health (OTCMKTS:BLUSF)

Receive News & Ratings for BELLUS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BELLUS Health and related companies with's FREE daily email newsletter.